Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire

Inclusion Criteria:

• Provision of informed consent
• Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex
• Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.

Exclusion Criteria:

• Allergy to substance of medication
• Pre-perimenopausal woman
• Woman not eligible for treatment